These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 30831644)

  • 1. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
    Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
    Guidara S; Seyve A; Poncet D; Leonce C; Bringuier PP; McLeer A; Sturm D; Cartalat S; Picart T; Ferrari A; Hench J; Frank S; Meyronet D; Ducray F; Barritault M
    J Neurooncol; 2024 Sep; 169(2):391-398. PubMed ID: 38937309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
    Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
    Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
    Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
    Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
    Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
    Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.
    Stegat L; Eckhardt A; Gocke A; Neyazi S; Pohl L; Schmid S; Dottermusch M; Frank S; Pinnschmidt H; Herms J; Glatzel M; Snuderl M; Schweizer L; Thomas C; Neumann J; Dorostkar MM; Schüller U; Wefers AK
    Acta Neuropathol; 2024 Sep; 148(1):40. PubMed ID: 39256213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
    Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
    Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
    [No Abstract]   [Full Text] [Related]  

  • 14. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
    Lu VM; Alvi MA; McDonald KL; Daniels DJ
    J Neurosurg Pediatr; 2019 Mar; 23(3):308-316. PubMed ID: 30544362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
    Zhao H; Fang X; Xue B
    Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological and molecular characteristics of pediatric gliomas: analysis of 111 cases].
    Xu H; Niu HL; Wang FH; Xu XK; Wang W; Yuan L; Chen K; Gao Q; Li LP; Xia JQ; Guo ZM
    Zhonghua Bing Li Xue Za Zhi; 2024 Sep; 53(9):922-928. PubMed ID: 39231745
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalamic H3K27M altered diffuse midline gliomas: Clinicopathological and outcome analysis.
    Chaturvedi A; Sadashiva N; Shukla D; Konar S; Krishna U; Beniwal M; Rao S; Santosh V; Saini J; Vazhayil V; Prabhuraj AR; Pruthi N; Arimappamagan A
    Clin Neurol Neurosurg; 2024 Sep; 244():108449. PubMed ID: 39053322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.